OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health, Inc. OPK secured $125 million of additional financing against mazdutide royalties, adding non-dilutive capital while keeping long-term participation in royalty growth in China. The transaction extends OPK’s use of royalty-backed funding as it continues to invest in a broad clinical pipeline.

The added liquidity can support development and operating needs without issuing common equity. The trade-off is that part of future royalty economics is committed to the financing.

OPKO Health, Inc. Price and Consensus

OPKO Health, Inc. price-consensus-chart | OPKO Health, Inc. Quote

OPK Turns Royalties Into $125 Million of New Capital

OPKO Health expanded its financing relationship with HealthCare Royalty, a KKR business, by issuing $125 million of additional senior secured notes backed by royalty interests from its mazdutide license agreement with Eli Lilly and Company LLY. The notes mature in 2044.

For investors, the structure provides capital without adding common shares. Lilly remains relevant to the underlying economics because mazdutide is part of its China development relationship with Innovent, keeping OPK’s royalty exposure tied to the product’s commercial progress in that market.

OPKO Health Keeps Exposure to Mazdutide Royalty Growth

Total payments on the new financing are capped at 1.5 times the funded amount. That limit gives OPK defined economics on the financing while avoiding a full sale of its mazdutide royalty interest.

OPKO Health retains long-term participation in mazdutide royalty growth in China. The arrangement therefore monetizes part of the future royalty stream today while preserving exposure if the underlying product generates higher royalties over time.

Image Source: Zacks Investment Research

OPK Gains Funding Flexibility Without Issuing Equity

The financing arrives as OPK continues to fund multiple clinical programs. Research and development expenses were $33.2 million in the second quarter of 2026, up 9.3% year over year, while full-year research and development spending is expected to remain between $125 million and $135 million.

ModeX has several clinical-stage programs, and OPK is also advancing OPK-88006, its once-weekly dual GLP-1/glucagon agonist, plus endocrine programs such as OPK8801001 and oral parathyroid hormone. Pfizer Inc. PFE, which commercializes NGENLA, also provides OPK with recurring profit-sharing economics from that partnered product.

OPKO Health Still Needs Pipeline and Diagnostics Execution

More capital does not remove the execution risks in OPK’s business. Several ModeX assets remain in Phase I development, MDX3001 has not yet entered human testing and OPK-88006 is still in early clinical development.

BioReference is also working through a smaller post-divestiture model. Management is targeting breakeven and sustainable profitability, but reimbursement uncertainty around the 4Kscore and the need to preserve testing volumes remain important considerations. OPK also continues to report operating losses despite recent improvement.

Image Source: Zacks Investment Research

OPK's Momentum Score Stands Out After the Financing

The financing improves OPK’s funding flexibility, but the investment picture remains balanced between pipeline optionality and execution risk. The company ended the second quarter with $314.4 million in cash, cash equivalents, marketable securities and restricted cash, while its development spending remains elevated.

OPK currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A is the strongest part of the Style Score profile, while the Growth Score of C, Value Score of F and VGM Score of C point to a more mixed setup. Style Scores are designed to complement the Zacks Rank, so the favorable momentum reading does not override the neutral near-term earnings-revision signal. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research